- The company's revenue over the past 12 months amounted to about $1.87 billion, an increase of 30.2% compared to 2020.
- OPKO Health's net debt was about $95.7 million in Q3 2021, down 60.4% from a year earlier and 48.2% down from Q2 2021.
- In Q4 2021, OPKO Health, in partnership with Pfizer, received regulatory approval from Australia, Canada for the use of Ngenla (somatrogon).
- BioReference Laboratories has concluded COVID-19 testing agreements with all major sports organizations, namely NHL, NFL, NBA, MLS.
- Increase in the volume of genetic testing in Q3 by 19.1% compared to Q3 2020.
For further details see:
OPKO Health: Undervalued Opportunity